User login
The study by El-Sahy and colleagues highlights the novel role of fecal microbiota transplant (FMT) in the treatment of irritable bowel syndrome (IBS). The safety and efficacy of this treatment was durable and provided sustained symptom relief for 3 years after FMT in this study. Those treated with donor feces had significantly lower IBS Severity Scoring System scores. Notably, patients with diarrhea-predominant IBS and those with mixed IBS had significantly higher response rates than did those with constipation-predominant IBS at 2 years post-FMT, but response rates coalesced at year 3. Those who lost clinical response at year 3 were responsive to retransplantation. This supports the idea of developing a protocol for FMT for the treatment of patients with IBS.
The study by Huang and colleagues investigates the long-term effects and potential mechanisms of action of transcutaneous electrical acustimulation (TEA) in patients with IBS with constipation (IBS-C) experiencing colonic transit issues and visceral hypersensitivity. Patients with IBS-C receiving TEA had increased frequency of spontaneous bowel movements and significant improvements in analog pain score compared with the placebo group. This supports the benefit of TEA for improving constipation and the concomitant symptoms by accelerating colonic transit and reducing rectal sensation. It can be inferred that the improvement of these symptoms will lead to enhanced quality of life in patients with IBS-C.
The study by Melchior and colleagues1 emphasizes the effect that IBS can have on a patient's life. Patients with IBS report reduced disease-specific quality of life. The cumulative impact of the demographic factors and the severity of psychological symptoms, somatic symptoms, and gastrointestinal symptoms are associated with decreased quality of life. The severity of this impact is determined by the combination of these factors and the level of severity at which they occur. This decrease in quality of life can lead to increased anxiety related to gastrointestinal function. It is important for providers to acknowledge the effect that gastrointestinal function has on the patient's life in a broader sense. The appreciation and understanding of the patient experience enhances the therapeutic relationship and shared decision-making between the patient and the healthcare provider.
Additional References
- Melchior C, Colomier E, Trindade IA, et al. Irritable bowel syndrome: Factors of importance for disease-specific quality of life. United European Gastroenterol J. 2022 Jul 13. Doi: 10.1002/ueg2.12277
The study by El-Sahy and colleagues highlights the novel role of fecal microbiota transplant (FMT) in the treatment of irritable bowel syndrome (IBS). The safety and efficacy of this treatment was durable and provided sustained symptom relief for 3 years after FMT in this study. Those treated with donor feces had significantly lower IBS Severity Scoring System scores. Notably, patients with diarrhea-predominant IBS and those with mixed IBS had significantly higher response rates than did those with constipation-predominant IBS at 2 years post-FMT, but response rates coalesced at year 3. Those who lost clinical response at year 3 were responsive to retransplantation. This supports the idea of developing a protocol for FMT for the treatment of patients with IBS.
The study by Huang and colleagues investigates the long-term effects and potential mechanisms of action of transcutaneous electrical acustimulation (TEA) in patients with IBS with constipation (IBS-C) experiencing colonic transit issues and visceral hypersensitivity. Patients with IBS-C receiving TEA had increased frequency of spontaneous bowel movements and significant improvements in analog pain score compared with the placebo group. This supports the benefit of TEA for improving constipation and the concomitant symptoms by accelerating colonic transit and reducing rectal sensation. It can be inferred that the improvement of these symptoms will lead to enhanced quality of life in patients with IBS-C.
The study by Melchior and colleagues1 emphasizes the effect that IBS can have on a patient's life. Patients with IBS report reduced disease-specific quality of life. The cumulative impact of the demographic factors and the severity of psychological symptoms, somatic symptoms, and gastrointestinal symptoms are associated with decreased quality of life. The severity of this impact is determined by the combination of these factors and the level of severity at which they occur. This decrease in quality of life can lead to increased anxiety related to gastrointestinal function. It is important for providers to acknowledge the effect that gastrointestinal function has on the patient's life in a broader sense. The appreciation and understanding of the patient experience enhances the therapeutic relationship and shared decision-making between the patient and the healthcare provider.
Additional References
- Melchior C, Colomier E, Trindade IA, et al. Irritable bowel syndrome: Factors of importance for disease-specific quality of life. United European Gastroenterol J. 2022 Jul 13. Doi: 10.1002/ueg2.12277
The study by El-Sahy and colleagues highlights the novel role of fecal microbiota transplant (FMT) in the treatment of irritable bowel syndrome (IBS). The safety and efficacy of this treatment was durable and provided sustained symptom relief for 3 years after FMT in this study. Those treated with donor feces had significantly lower IBS Severity Scoring System scores. Notably, patients with diarrhea-predominant IBS and those with mixed IBS had significantly higher response rates than did those with constipation-predominant IBS at 2 years post-FMT, but response rates coalesced at year 3. Those who lost clinical response at year 3 were responsive to retransplantation. This supports the idea of developing a protocol for FMT for the treatment of patients with IBS.
The study by Huang and colleagues investigates the long-term effects and potential mechanisms of action of transcutaneous electrical acustimulation (TEA) in patients with IBS with constipation (IBS-C) experiencing colonic transit issues and visceral hypersensitivity. Patients with IBS-C receiving TEA had increased frequency of spontaneous bowel movements and significant improvements in analog pain score compared with the placebo group. This supports the benefit of TEA for improving constipation and the concomitant symptoms by accelerating colonic transit and reducing rectal sensation. It can be inferred that the improvement of these symptoms will lead to enhanced quality of life in patients with IBS-C.
The study by Melchior and colleagues1 emphasizes the effect that IBS can have on a patient's life. Patients with IBS report reduced disease-specific quality of life. The cumulative impact of the demographic factors and the severity of psychological symptoms, somatic symptoms, and gastrointestinal symptoms are associated with decreased quality of life. The severity of this impact is determined by the combination of these factors and the level of severity at which they occur. This decrease in quality of life can lead to increased anxiety related to gastrointestinal function. It is important for providers to acknowledge the effect that gastrointestinal function has on the patient's life in a broader sense. The appreciation and understanding of the patient experience enhances the therapeutic relationship and shared decision-making between the patient and the healthcare provider.
Additional References
- Melchior C, Colomier E, Trindade IA, et al. Irritable bowel syndrome: Factors of importance for disease-specific quality of life. United European Gastroenterol J. 2022 Jul 13. Doi: 10.1002/ueg2.12277